RMD · Q4 2025 Earnings

The dominant tonal shift this quarter is the recharacterization of gross margin expansion. In prior commentary, the recovery from prior-year gross margins was framed as a normalization story — supply chain costs unwinding, freight rates falling, component availability improving. On this call, in response to an analyst question on the gross margin guide, CEO Mick Farrell said it directly: "not a one-and-done. There was some good reset and some catch-up, but actually there's some sustainable improvements that allows us to give that guidance of 61 to 63." CFO Brett Sandercock anchored the same point operationally — sea-to-air freight ratios back to pre-COVID levels, component cost initiatives compounding, AirSense 10-to-11 platform transition still contributing. Putting a 61–63% range on FY26 — with Q4 already inside the band — signals management believes procurement, manufacturing and logistics initiatives have a multi-year runway. This is the single most important reframing on the print.

Vertical integration in diagnostics is the second shift. Historically ResMed positioned home sleep testing as a job for the HME and lab ecosystem. With VirtuOx, Ectosense and Somnoware now in the portfolio, Farrell's framing — offered in response to an analyst question on the VirtuOx roadmap — is that "if there isn't an ecosystem of people driving home sleep apnea testing, smooth software, and scalable home sleep apnea testing, then ResMed as the global leader in this space has to step in." The strategic implication: ResMed will own more of the patient funnel directly rather than wait for partners to scale it. Expect more diagnostics-adjacent capital allocation.

The tone on CMS competitive bidding is cautious but engaged rather than dismissive. Farrell explicitly declined to forecast impact, saying "I simply cannot get too specific, as CMS has not yet announced any of the details as to what product categories included, nor the timeframe." He flagged his incoming AdvaMed chairmanship and ResMed's "long-standing track record" of constructive engagement with policymakers as the mechanism for influencing the comment period. The posture is "we will work the process" rather than "this is a swing factor" — but management is not pre-declaring it benign either. Investors should treat scope and timing of the next bidding round as a genuinely open variable.

GLP-1 commentary this quarter was lighter than in prior calls. Management framed GLP-1 promotion as a source of "greater awareness of sleep apnea" among the primary care physician groups GLP-1 manufacturers target — the same PCPs ResMed is reaching with its own CME programs. The disclosed adherence metric this quarter was on the CME effort, not GLP-1 cohorts directly: 75% of CME course graduates indicate post-training that they intend to change their clinical practice in sleep health. ROAS on demand-generation spend was described as "many multiples of the investment." The framing is that ResMed's physician-education spend captures the awareness GLP-1 promotion creates.

The increase to ~$150M/quarter in buybacks alongside a 13% dividend raise signals management sees cash flow conversion (FCF margin 32.3% in FY25) as durable enough to fund both capacity expansion (Calabasas opening) and steady return of capital.